Caris Introduces CARIS ASSURE™ Liquid Biopsy Assay
On June 3, Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, introduced its Caris Assure™ liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. (Read more)
Caris Opens New Liquid Biopsy Laboratory Facility
On April 25, Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced the opening of a new liquid biopsy laboratory in Phoenix, Arizona, which will further expand the company’s molecular profiling capabilities, which include tumor profiling and innovative blood-based cancer diagnostics. This $45 million investment in the company’s laboratory facilities will enable the company to continue to develop and launch its blood-based diagnostic assay, Caris Assure™. (Read more)
Caris POA Presents 45 Studies at ASCO 2022 Annual Meeting
On May 26, Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) collectively presented 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which was held from June 3-7, 2022. (Read more)
(3) oral discussions focused on difficult to treat tumors and aggressive tumor types with low survival rates:
Other notable studies among the 45 accepted abstracts focused on key topics in oncology such as the tumor microenvironment, mechanisms of therapeutic resistance and rare biomarkers:
Share to: